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O R I G I N A L  R E S E A R C H
Abstract: The angiotensin-converting enzyme (ACE), a protease involved in blood pressure
regulation, has been implicated as an important candidate gene for Alzheimer’s disease (AD).
This study investigated whether the ACE gene insertion–deletion (ID) polymorphism is
associated with risk of developing dementia of Alzheimer’s type (DAT) in an Arab–Israeli
community, a unique genetic isolate where there is a high prevalence of DAT. In contrast to
several other studies, we found no evidence of an association between this polymorphism and
either DAT or age-related cognitive decline (ARCD).
Keywords: angiotensin-converting enzyme, dementia of the Alzheimer’s type, age-related
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Introduction
Alzheimer’s disease (AD) is a catastrophic affliction of the middle and later years of
life. Clinically, it is marked by an irreversible decline in mental abilities, including
progressive loss of memory, confusion, and dementia, and culminates in childlike
helplessness. In the United States, the incidence of AD is exponentially increasing
and is projected to affect 8.64 million people by the year 2047 (Grossberg 2003).
Median survival times range from 8.3 years for persons diagnosed at age 65, to 3.4
years for persons diagnosed at age 90 (Brookmeyer et al 2002).
Angiotensin-converting enzyme (ACE) catalyzes the conversion of angiotensin I
into a physiologically active peptide, angiotensin II. This reaction is an important
process in blood pressure regulation. In addition to this well known physiologic role,
ACE is able to cleave other proteins, including bradykinin and substance P, and has
been shown to inhibit and cleave amyloid β-peptide (Aβ) aggregation and amyloid
plaque formation in vitro (Hu et al 2001). ACE may contribute to the pathogenesis
of AD.
To test the hypothesis of association between ACE and DAT, we evaluated an
insertion–deletion (ID) polymorphism in the ACE gene as a potential risk factor for
dementia of the Alzheimer’s type (DAT) in an Arab community in Wadi Ara, Israel.
The population comprised 853 persons over the age of 65 (Bowirrat et al 2001;
Bowirrat, Friedland, Farrer, et al 2002). Family studies revealed that more than one-
third of DAT cases are members of one extended family. We hypothesized that DAT
in Wadi Ara may be due to a founder effect enhanced by consanguinity; thus, a
specific disease susceptibility allele may be overrepresented in cognitively impaired
subjects compared with cognitively healthy residents. Our results suggest that the
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ACE-ID polymorphism is not associated with either DAT
or age-related cognitive decline (ARCD) in this Arab
community.
Methods and results
Subjects were sourced from a prevalence study of dementia
conducted in Wadi Ara, a geographically defined area in
northern Israel comprising three Arab villages (Bowirrat et
al 2001). Among the original list of 853 residents aged 65
years and older (prevalence date, October, 1995), 823 (363
males and 460 females) were available and consented to
participate in the study. Only 30 patients (23 females and 7
males) were excluded from the original list of the study (853)
because they did not fulfill the diagnostic criteria for DAT
and ARCD (they were classified with other medical
conditions). Among the excluded females (n = 23), 19
suffered from vascular dementia (VaD), 1 patient had
Parkinson’s disease (PD), and 3 had pseudodementia.
Among the excluded males (n = 7), 5 suffered from PD and
2 patients were diagnosed with VaD. The sex-specific
prevalence of DAT among males and females was
53/363 = 14.6% and 115/460 = 25%, respectively; and the
sex-specific prevalence of ARCD among males and females
was 118/354 = 33.3% and 236/354 = 66.6%, respectively.
These subjects were interviewed and examined by an Arabic-
speaking neurologist (AB). Each subject underwent a battery
of standard cognitive tests modified to fit the cultural and
linguistic characteristics of this community (Bowirrat et al
2001). The diagnosis of DAT and ARCD was determined
using DSM-IV criteria (APA 1994). Those with a medical
history and laboratory or cognitive test results that suggested
the presence of other illnesses, such as vascular dementia,
Parkinson’s disease, normal-pressure hydrocephalus, or
pseudodementia (depression), were excluded. Peripheral
blood samples were obtained from the 650 subjects for DNA
analysis.
To genotype the ACE-ID polymorphism, 2 polymerase
chain reactions (PCRs) were performed. In the first reaction,
primers that flank the ID polymorphism were used to
amplify DNA from each subject (5´-CTGGAGACC
ACTCCCATCCTTTCT and 5´-TTGATGAGTTCCAC
GTATTTCG). The resulting PCR product was analyzed on
a 2% agarose gel for the presence or absence of the 287-bp
insertion–deletion polymorphism. Because this reaction
frequently fails to detect the insertion variant, a second PCR
reaction was performed that specifically amplifies the allele
containing the insertion (primers 5´-CTGGGATTA
CAGGCGTGATACA and 5´-TTGATGAGTTCCAC
GTATTTCG). The data from both reactions were used to
establish the ACE-ID genotype. For statistical analysis, the
Hardy-Weinberg equilibrium (HWE) was assessed for each
group (DAT, ARCD, normal). Allele and genotype
frequencies were compared among groups by a χ2 test.
The results of the ACE (ID) genotyping (Table 1) showed
that the frequency of the I allele was 32% in cognitively
normal control, 26% in DAT cases (p = 0.2223), and 32%
in ARCD cases (p = 0.9559). The genotype frequency
distribution in the control groups were also similar to those
for DAT cases (p = 0.3731) and ARCD cases (p = 0.9973).
Therefore, our results suggest that the ID polymorphism
within ACE is not associated with DAT or ARCD in this
Arab community (Table 1).
Discussion
AD is the most overdiagnosed and misdiagnosed disorder
of mental functioning in older adults. Part of the problem,
is that many other disorders show symptoms that resemble
those of AD. The crucial difference, however, is that many
of these disorders – unlike AD – may be stopped, reversed,
or cured. Based on these findings, clinical diagnosis of AD
has been referred to as “a diagnosis by exclusion”, and one
that can only be made in the face of clinical deterioration
over time. There is no specific clinical test or finding that is
unique to AD. Hence, all disorders that can bring on similar
symptoms must be systematically excluded. The “classical”
senile plaques and the neurofibrillary tangles seen in an AD
Table 1 Genotypic and allelic frequencies among ARCD, DAT,
and cognitively normal control
ACE-ID Normal ARCD DAT
II 8 (7.14) 3 (6.82) 5 (5.88)
DI 56 (50) 22 (50) 35 (41.18)
DD 48 (42.86) 19 (43.18) 45 (52.94)
f(I) 72 (32.14) 28 (31.82) 45 (26.47)
Abbreviations: ACE, angiotensin-converting enzyme; I, insertion allele; D,
deletion allele; ARCD, age-related cognitive decline; DAT, dementia of
Alzheimer’s type; f(I), frequency of the insertion allele.
Table 1a Genotypic p-value
Group ARCD Normal
DAT 0.5745 0.3731
ARCD – 0.9973
Table 1b Allelic p-value
Group ARCD Normal
DAT 0.3660 0.2223
ARCD – 0.9559
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brain at autopsy typically are the only definitive diagnosis
of the disease.
We did not observe an association between the ACE-ID
polymorphism and DAT or ARCD in the elderly Arab
population of Wadi Ara. Notably, inherited susceptibility
for DAT in Wadi Ara is also not accounted for by the ApoE
ε4 allele. Indeed, the frequency of ApoE ε4 among DAT,
ARCD, and control was 0.027, 0.033, and 0.029,
respectively (Bowirrat et al 2000).
Nonetheless, the relationship between ACE and AD is
controversial. Several studies have implicated the ID
polymorphism and risk of AD (Narain et al 2000; Cheng et
al 2002; Kehoe et al 2003; Elkins et al 2004; Tian et al 2004),
while other studies failed to find an association
(Myllykangas et al 2000; Taylor et al 2001; Buss et al 2002;
Lendon et al 2002; Monastero et al 2002; Harrap et al 2003;
Panza et al 2003). Moreover, the pattern of association has
been confusing, with some studies showing an association
with the I allele (Alvarez et al 1999; Yang et al 2000; Hu et
al 2001), while others with the D allele (Amouyel et al 1996;
Palumbo et al 1999; Crawford et al 2000; Farrer et al 2000;
Richard et al 2001).
The reasons for the disparity in results across studies
may be due to differences in ethnic background, different
environmental factors, or subject misclassification. To date,
few studies have examined the frequency of the ACE
genotypes in autopsy-confirmed cases of AD, or investigated
the potential effect of these ACE genotypes on the pathology
of the disorder. In one autopsy series, the ACE genotype
was not associated with the amount of Aβ40, Aβ42, or
pathological tau protein deposited within the frontal cortex,
or in the extent of amyloid angiopathy in the brain, whether
ApoE ε4 allele was present or not (Lendon et al 2002). The
only other autopsy-based study of ACE (based on an elderly
Finnish population) also failed to detect an association with
ACE (Myllykangas et al 2000). In the Arab community,
autopsy is prohibited for religious and traditional reasons.
Other limitations of our study are the absence of biomarkers
and complete biochemical examinations, and the low
number of neuroimaging performed. These helpful clinical
techniques are necessary to improve our clinical diagnosis
of DAT and are required to differentiate it from similar
clinical manifestation that mimic the presentation of
dementia.
A possible biological explanation for an association
between ACE and AD is still unclear. The insertion allele
appears to reduce ACE expression, and DD homozygotes
and ID heterozygotes have more circulating ACE than II
homozygotes: 65%, and 31%, respectively (Rieder et al
1999). This increased activity of the D allele may alter Aβ
deposition by a direct proteolytic mechanism (Kehoe et al
2003). Alternatively, ACE may have an indirect role in the
progression of AD. The ID polymorphism has also been
implicated in various conditions including hypertension
(Zaman et al 2002; Hopkins and Hunt 2003), coronary heart
disease (Arbustini et al 1995; Kauma et al 1996),
cardiomyopathy (Pfohl et al 1998), stroke (de la Torre et al
2002), and juvenile rheumatoid arthritis (Alsaeid et al 2003).
Other studies don’t confirm these associations (see Ueda et
al 1995; Hung et al 1999; Harrap et al 2003).
Several studies suggest that there may be a relationship
between cardiovascular lesions and the severity and
progression of AD (Snowdon et al 1997; Zuliani et al 2001;
Bowirrat, Friedland, Korczyn 2002; de la Torre 2002;
Korczyn 2002). In summary, in the present study, we found
a lack of association between ACE and DAT. Our previous
studies have not determined any gene that may explain the
high prevalence of DAT in this community, but we have
found high prevalence of vascular dementia (VaD) following
stroke. Indeed, the prevalence of VaD constitutes 5.9% of
the total elderly Arab population in Wadi Ara and about
22% of the total dementia population (Bowirrat, Friedland,
Korczyn 2002). This prevalence of VaD (22%) is extremely
high compared with VaD patients who accounted for only
6% of all dementia patients identified by Fillit and Hill
(2002). Given the role of the ACE gene in vascular disease
as well as in AD, the ability to detect association with AD
may be complex. On the other hand, and in light of the high
frequency of VaD in this population, a new study to evaluate
the role of ACE in VaD is essential.
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